European Innovation Council

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

AlzeCure Pharma AB is a pharmaceutical company based in Huddinge, Sweden, that specializes in developing drug therapies aimed at treating diseases affecting the central nervous system, with a particular emphasis on Alzheimer's disease. Established in 2012, the company is advancing multiple drug candidates through its research platforms, NeuroRestore and Alzstatin, among others. Current projects include ACD855, which is undergoing Phase I clinical trials for sleep disruptions, traumatic brain injuries, and Alzheimer's disease, along with several other candidates targeting Alzheimer's: ACD856, ACD679, and ACD680. Additionally, AlzeCure is developing ACD857 for eye and ear conditions, and VR1 for neuropathic pain, alongside TrkA-NAM for osteoarthritic pain. Through its focused research initiatives, AlzeCure Pharma aims to address significant unmet medical needs in neurodegenerative diseases.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Patient-specific right heart pumps that free patients from heavy battery packages and increase patient's quality of life.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Quantune Technologies is a deep tech startup specializing in optics and photonics technology. The company focuses on developing advanced infrared spectrometers that facilitate continuous and non-invasive health monitoring. By miniaturizing traditional laboratory equipment used for molecular analysis into compact modules, Quantune enables both biomedical consumer devices and industrial applications. This innovation allows clients to efficiently conduct real-time monitoring and analysis of chemical compounds and emissions, providing accessible solutions for a range of novel applications.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its proprietary Trillium™ technology, designed to treat Tricuspid Valve Regurgitation. Innoventric's device features a functional tricuspid valve replacement that employs cross-caval anchoring and a multi-valve design, aimed at enhancing blood flow regulation. The company has conducted over ten implantations of the Trillium™ technology as part of its first human clinical trial in Europe. Additionally, Innoventric maintains a comprehensive patent portfolio for the Trillium™ and related technologies, positioning itself as a key player in the structural heart medical device sector.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

King's College London (informally King's or KCL) is a public research university located in London, United Kingdom, and a constituent college of the federal University of London. King's is arguably the third-oldest university in England, having been founded by King George IV and the Duke of Wellington in 1829, receiving its royal charter in the same year. St Thomas' Hospital, which is now a teaching hospital of King's College London School of Medicine, has roots dating back to 1173. In 1836, King's became one of the two founding colleges of the University of London. King's is based in the centre of London and organised into nine academic schools, spread across four Thames-side campuses in central London and another in Denmark Hill in south London. It is one of the largest centres for graduate and post-graduate medical teaching and biomedical research in Europe; it is home to six Medical Research Council centres for <a href="https://www.dissertationcorp.co.uk/">dissertation help</a> , the most of any British university, and is a founding member of the King's Health Partners academic health sciences centre. King's has around 25,000 students and 6,113 staff and had a total income of £587 million in 2012/13, of which £164 million was from research grants and contracts. King's is a world-leading university, currently ranked 19th in the world (6th in the UK and 8th in Europe) in the 2013 QS World University Rankings, and 38th in the world (6th in the UK and 9th in Europe) in the 2013 Times Higher Education World University Rankings. There are currently 12 Nobel Prize laureates amongst King's alumni and current and former faculty. King's is a member of the Association of Commonwealth Universities, the European University Association, the Russell Group and Universities UK. It forms part of the 'golden triangle' of British universities.

Vitestro is a developer of innovative medical robotic devices focused on enhancing patient care through autonomous blood drawing technology. The company's flagship device employs multi-dimensional ultrasound detection to identify nerves and arteries, utilizing deep learning algorithms to minimize the risk of arterial complications during clinical procedures. This advancement aims to streamline the blood collection process in hospitals and clinical laboratories, ultimately enabling healthcare professionals to perform operations with greater precision and improve overall patient health outcomes.

Vitestro is a developer of innovative medical robotic devices focused on enhancing patient care through autonomous blood drawing technology. The company's flagship device employs multi-dimensional ultrasound detection to identify nerves and arteries, utilizing deep learning algorithms to minimize the risk of arterial complications during clinical procedures. This advancement aims to streamline the blood collection process in hospitals and clinical laboratories, ultimately enabling healthcare professionals to perform operations with greater precision and improve overall patient health outcomes.

Sentante is a medical technology company specialising in the development of robotic teleoperated systems for endovascular procedures. Their core product enables physicians to perform complex surgeries remotely, reducing their exposure to harmful X-rays and expanding telesurgery capabilities.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

RespiQ is a healthtech startup focused on developing portable, non-invasive breath analysis technology for the early detection and management of respiratory diseases. The company employs advanced emission spectroscopy and artificial intelligence to identify volatile organic compounds in breath, facilitating real-time detection of conditions such as COPD exacerbations. RespiQ emphasizes affordability, portability, and user-friendliness to democratize access to advanced diagnostics, thereby enhancing patient outcomes and reducing healthcare costs. In addition to its primary focus on respiratory diseases, RespiQ's versatile platform technology has potential applications for conditions such as asthma, lung cancer, and infectious diseases. The company also offers an intuitive app that provides personalized health insights, allowing users to monitor changes in their health and make informed dietary choices, ultimately empowering individuals to improve their overall well-being.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.

Cellevate AB, founded in 2014 and based in Lund, Sweden, is an innovative biotech company specializing in the development of advanced cell culture systems. The company's flagship product, 3D NanoMatrix, consists of nanofiber scaffolds designed to serve as realistic in-vitro models for scientific research and development across various industries including automotive, construction, defense, electronics, energy, environment, and healthcare. These nanofiber scaffolds are created through a patented manufacturing process that produces porous and consistent networks of nanofibers, enhancing the realism of cell culture systems used in upstream bioprocessing.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

EyeControl is a medical technology company that develops innovative communication solutions for individuals with severe speech impairments, such as those affected by locked-in syndrome or ALS. Their flagship product is an intuitive glass frame equipped with an infrared camera, which translates eye movements into spoken commands via a connected computer and earphones/speaker. This device aims to enhance patients' quality of life by facilitating easier communication and improving access to healthcare services.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Ligence is a Deep Tech startup based in Lithuania, founded by a team of medical doctors with expertise in artificial intelligence. The company focuses on developing innovative solutions for healthcare, particularly in the field of cardiology. Its flagship product, Ligence Heart, automates the analysis of heart ultrasound images using advanced deep learning algorithms. This technology is designed to recognize various heart image views and perform necessary measurements automatically, allowing medical professionals to bypass manual calculations. By streamlining the analysis process, Ligence Heart enhances the efficiency of cardiac ultrasound assessments, enabling cardiologists and sonographers to devote more time to patient care and significantly reduce analysis time.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Rockfield Medical Devices is a forward-thinking small to medium enterprise focused on human-centered design within the medical device sector. Founded by an industry expert, the company comprises a team of recognized professionals from medical device research and design. Rockfield is dedicated to becoming a global leader in the enteral feeding market, aiming to enhance user satisfaction through innovative, plug-and-play technologies that prioritize design, usability, and mobility. The company's platform significantly improves the mobility and quality of life for individuals relying on tube feeding, while also streamlining technical support and reducing maintenance costs for sales partners. By offering a user-friendly, lightweight, and discreet mobile feeding system, Rockfield Medical Devices seeks to transform service models in the enteral feeding community.

Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Trisol Medical is a medical device company focused on addressing tricuspid regurgitation through innovative treatment solutions. The company specializes in the development of a transcatheter tricuspid replacement valve, which is engineered from a nitinol frame and features specially designed leaflets. This design effectively eliminates tricuspid regurgitation while preserving the function of the right ventricle. Trisol Medical's offerings aim to provide comprehensive treatment for patients suffering from tricuspid regurgitation and associated right ventricle dysfunction, enhancing patient outcomes and quality of life.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Handiscover Sweden AB is an online booking platform specializing in accommodations for individuals with physical disabilities. Founded in 2014 by Sebastien Archambeaud in response to personal experiences as a parent of a child with a muscle disease, the company is headquartered in Malmö, Sweden. Handiscover features a distinctive classification system that allows users to select accommodations based on varying levels of mobility and physical needs. This community-based platform not only enables individuals with disabilities to find suitable vacation rentals but also assists companies and municipalities in gathering and presenting essential accessibility data. By focusing on the unique requirements of its users, Handiscover aims to enhance the travel experience for people with disabilities, making it easier for them to discover and book accessible holiday accommodations.

Elgan Pharma is a biotechnology company specializing in neonatology, primarily focused on addressing the medical challenges faced by premature infants. The company develops innovative therapies using nanotechnology aimed at preventing visual impairment, a significant concern for preterm babies. By targeting the multifactorial causes of visual disabilities, Elgan Pharma enables healthcare professionals to improve visual outcomes and reduce the risk of long-term disabilities in this vulnerable population. Through its advancements in late-stage development, the company is committed to enhancing the quality of care for premature infants and addressing critical developmental difficulties associated with their early birth.

Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

Plasmacure, headquartered in Eindhoven, Netherlands, is a medical technology company focused on developing innovative solutions for chronic wound healing, with a particular emphasis on diabetic foot wounds. The company's core product is a patented cold plasma solution designed to kill bacteria, stimulate cell proliferation, and improve microcirculation, thereby reducing the risk of amputation and enhancing patients' quality of life.

Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices for treating brain disorders. Its proprietary device, SonoCloud®, is an intracranial ultrasound implant that, when used in conjunction with an intravenous microbubble agent, temporarily opens the blood-brain barrier. This mechanism significantly enhances the delivery of therapeutic molecules to the brain, potentially providing new treatment options for debilitating neurological conditions. Through its technology, Carthera aims to enable healthcare professionals to address challenging brain disorders more effectively.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Escala Medical is focused on developing a pioneering medical device aimed at treating pelvic organ prolapse (POP) in women. The company has created a minimally invasive, incision-free, and mesh-free repair system that addresses the long-standing need for effective POP treatment options. This innovative device allows for a nonsurgical approach that can be performed in outpatient and office settings, ensuring a safe and quick procedure with minimal discomfort for patients. By connecting the vaginal apex to the sacrospinous ligament without incisions, Escala Medical's technology preserves organ functionality while providing a much-needed solution for those affected by POP.

Escala Medical is focused on developing a pioneering medical device aimed at treating pelvic organ prolapse (POP) in women. The company has created a minimally invasive, incision-free, and mesh-free repair system that addresses the long-standing need for effective POP treatment options. This innovative device allows for a nonsurgical approach that can be performed in outpatient and office settings, ensuring a safe and quick procedure with minimal discomfort for patients. By connecting the vaginal apex to the sacrospinous ligament without incisions, Escala Medical's technology preserves organ functionality while providing a much-needed solution for those affected by POP.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Scandinavian Real Heart AB is a medical technology company focused on creating advanced artificial heart solutions. The company's flagship product, the Total Artificial Heart (TAH), aims to closely replicate the natural pumping function, pressure ratios, and pulse of a healthy heart. Designed primarily as a transitional solution, the TAH is intended for patients awaiting heart transplants, offering enhanced functionality compared to existing devices in the market. Through its innovative approach, Scandinavian Real Heart seeks to address the critical needs of individuals facing severe heart conditions and improve their chances of survival while awaiting surgical intervention.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovation aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant global market given the high prevalence of diabetic foot ulcers.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Quantune Technologies is a deep tech startup specializing in optics and photonics technology. The company focuses on developing advanced infrared spectrometers that facilitate continuous and non-invasive health monitoring. By miniaturizing traditional laboratory equipment used for molecular analysis into compact modules, Quantune enables both biomedical consumer devices and industrial applications. This innovation allows clients to efficiently conduct real-time monitoring and analysis of chemical compounds and emissions, providing accessible solutions for a range of novel applications.

GrayMatters Health is a health technology company focused on developing digital therapeutics for mental disorders by enabling volitional regulation of brain processes. The company aims to address mental health and neurological disorders through its innovative solutions, which empower healthcare professionals with neuroscience-based technology. By targeting brain biomarkers associated with these conditions, GrayMatters Health enhances the efficacy, safety, and accessibility of mental healthcare. This approach provides patients with streamlined treatment options, allowing them to manage their disorders more effectively and conveniently.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in deep thermotherapy specifically for head and neck cancer treatment. The company has developed a unique medical device that employs proprietary thermal technology and interactive software to provide localized heating, enhancing the effectiveness of conventional therapies like radiotherapy and chemotherapy, which often have toxic side effects. Sensius' innovative approach has shown promising results, with a study indicating that 81.8% of treated patients achieved a complete response within 12 weeks of radiotherapy. With interest from twenty potential buyers, Sensius is in the process of obtaining CE marking for its device and has plans to expand its applications to other types of cancer in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in deep thermotherapy specifically for head and neck cancer treatment. The company has developed a unique medical device that employs proprietary thermal technology and interactive software to provide localized heating, enhancing the effectiveness of conventional therapies like radiotherapy and chemotherapy, which often have toxic side effects. Sensius' innovative approach has shown promising results, with a study indicating that 81.8% of treated patients achieved a complete response within 12 weeks of radiotherapy. With interest from twenty potential buyers, Sensius is in the process of obtaining CE marking for its device and has plans to expand its applications to other types of cancer in the future.

Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Syntach is a medical technology company focused on developing innovative cardiac support devices aimed at enhancing the care of individuals suffering from heart failure. The company's flagship product is a permanent, active implant designed to restore the impaired movement of the mitral valve while providing natural support to the heart. This device can be inserted using minimally invasive techniques and is smaller than traditional left ventricular assist devices (LVADs), which contributes to a better quality of life for patients and reduces the risk of complications. Syntach's technology is intended to benefit both men and women who require cardiac support.

Ganymed Robotics SAS, established in 2018 and headquartered in Paris, France, specializes in the development of advanced robotics technologies tailored for orthopedic surgeons. The company's primary focus is on creating a therapeutic device designed to enhance surgical precision during knee replacement procedures. This innovative technology aims to improve patient outcomes, surgeon experience, and overall efficiency of care delivery by leveraging robotic assistance to reduce operating time.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Newronika is a company dedicated to restoring brain and body functions through innovative neuro-modulation technologies. It translates extensive expertise in biosignal decoding into clinical applications aimed at enhancing treatments, health, and overall wellness. By utilizing a therapeutic device that employs a retro-activity system, Newronika records brain activity and modulates neuro-stimulation to analyze and interpret bio-signals. This technology ensures that patients receive the appropriate stimulation at critical moments, enabling them to engage in normal daily activities and improve their quality of life. Founded as a spin-off from two prominent Italian research institutions, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika prides itself on a multidisciplinary team of scientists specializing in various fields, including neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

Avatar Medical is a developer of a virtual reality medical platform that creates 3D patient avatars to assist surgeons in visualizing medical images. By generating interactive representations based on medical data, the platform enables clinicians to accurately and instantly access critical clinical information. This innovative approach not only enhances the understanding of surgical options but also facilitates the training of medical fellows and improves patient engagement. Avatar Medical aims to transform how medical professionals interact with imaging data, ultimately contributing to better surgical outcomes and patient care.

VIVAN Therapeutics is a company focused on developing personalized cancer therapeutics aimed at revolutionizing cancer care. Utilizing a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, VIVAN offers a comprehensive genomics-based drug screening service that integrates blockchain technology. The company's approach includes the Personal Discovery Process (PDP), which treats each patient as a unique case by engineering their tumor's genetic complexity into a model using fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. This innovative strategy aims to provide less toxic and more affordable treatment options, enhancing the effectiveness of cancer care through tailored recommendations and the development of new diagnostics and decision support tools.

Axiles Bionics is a Brussels-based company founded in 2018, specializing in the development of advanced robotic ankle-foot prostheses for lower limb amputees. As a spin-off from the Free University of Brussels, Axiles Bionics focuses on enhancing the quality of life for individuals with limb disorders through innovative assistive robotics. The company’s bionic prosthetic feet combine the strength and flexibility of a natural ankle with robotic capabilities, allowing for improved movement and support. By bringing next-generation technology to the market, Axiles Bionics aims to provide users with smarter and more effective solutions for mobility and daily activities.

Vigor Medical Technologies Ltd. specializes in the development and commercialization of innovative medical devices aimed at treating chest trauma and facilitating thoracic and abdominal drainage. With over 4 million cases of chest trauma reported annually, which is a leading cause of accidental death, the company addresses a critical need in emergency medicine. Vigor's products include self-fixation sealing devices that effectively prevent lung and heart collapse, conditions that can be fatal if not promptly identified and managed. Additionally, the company's devices feature a hermetic seal and an open drainage shaft, allowing them to seal off wounds regardless of contamination from dirt, blood, or other materials. This technology is designed to support both military and civilian first aid organizations, as well as hospitals, enhancing the effectiveness of emergency care in critical situations.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

CorTec is a developer and manufacturer specializing in medical device components and active implantable systems for neuromodulation applications and brain-computer interfaces. With a decade of intensive research and development, the company has created the CorTec Brain Interchange System, a unique platform technology designed to facilitate the development of novel therapies for neurological diseases. This system features laser-structured AirRay electrode arrays that provide a reliable and flexible interface for permanent brain recordings, gently conforming to the brain's curvature. A biocompatible ceramic encapsulation houses an electronics unit that preprocesses data, while a custom-developed microchip amplifies neuronal signals across multiple channels and digitizes them at a high sampling rate. The system operates without a battery, utilizing an inductive power supply to eliminate the need for surgical replacements. Additionally, CorTec supports Medtech companies and startups in neurotechnology by providing components and services related to the Brain Interchange System.

AkknaTek is a company specializing in the development of patented optical testing technology aimed at improving patient visual outcomes, particularly in the context of intraocular lenses (IOLs). Its flagship product is a lens reviewer designed to assist in the postoperative management of dislocated IOLs, making the treatment process more intuitive and accessible for clinics. By minimizing the risk of unexpected refractive complications following cataract surgery, AkknaTek's technology not only enhances the safety and effectiveness of IOL implants but also reduces the likelihood of the need for additional refractive procedures. The company's innovative approach contributes significantly to better postoperative care for patients undergoing cataract surgery.

ABCDx SA is a privately-funded company based in Geneva, Switzerland, founded in 2014 by three experts in the field of brain biomarkers. The founders include two prominent researchers from the Faculty of Medicine at the University of Geneva and the Vall d’Hebron Research Institute, who are recognized for their contributions to biomarker discovery and validation. The third founder brings extensive experience in the diagnostic and pharmaceutical industries. ABCDx specializes in the development and validation of biomarker and biomarker panel tests aimed at enhancing the diagnosis and treatment of brain injuries. The company's offerings are designed to identify and assess patients at risk of severe long-term complications stemming from traumatic injuries, strokes, and post-stroke infections. Through its innovative approach, ABCDx aims to improve patient outcomes in the realm of brain health.

NC Biomatrix is a company focused on developing innovative medical therapies aimed at restoring the natural biomechanics of the spine to alleviate lower back pain. The company specializes in non-invasive treatments, offering an injectable viscous gel that targets the underlying causes of low back pain. By providing a new treatment option for individuals suffering from these common issues, NC Biomatrix aims to improve patient outcomes and enhance quality of life.

Afon Technology specializes in the development of non-invasive blood glucose monitoring devices aimed at benefiting individuals with diabetes. The company’s innovative technology allows for real-time, pain-free tracking of blood glucose levels, offering features such as continuous detection, potential pre-diabetic identification, and alarm alerts for high and low glucose levels. Users can access trend profiles and time-in-range statistics through a user-friendly app compatible with both iOS and Android systems. Additionally, Afon Technology’s device can transform any smartwatch into a glucose monitoring tool, providing fast and accurate measurements, data logging, and personalized health trends. This approach enhances daily management for diabetics, ultimately reducing the risk of diabetes-related complications.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly in the realm of MRI technology. The company manufactures cylindrical phantoms that streamline the preparation process by eliminating the need for multiple sample vials, facilitating more efficient calibration. Its offerings include a cloud-based data analysis platform that ensures traceability to standardized values, allowing clinicians, medical physicists, and radiographers to obtain consistent quantitative measurements of diseases across different patients, scanners, and clinical environments. By enhancing the precision of MRI imaging, Gold Standard Phantoms aims to improve diagnostic accuracy and potentially reduce healthcare costs.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

timeisbrain is a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

Vésale Pharma is a pharmaceutical company that collaborates with internationally recognized research organizations to develop innovative healthcare solutions. The company focuses on producing pharmaceutical products designed to enhance health and well-being for individuals across various stages of life. Vésale Pharma's offerings are tailored to address specific areas such as dermatology, gastroenterology, women's health, immunity, and pregnancy. Notably, its products are formulated to have no side effects and are suitable for all body types, allowing patients to maintain their health and fitness effectively.